Results 41 to 50 of about 19,810 (255)
Clinical and Translational Radiation Oncology, 2020 Background: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma.
Philipp E. Hartrampf +9 more
doaj +1 more source
Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents. [PDF]
, 2016 OBJECTIVE: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide (pituitary adenylate cyclase-activating peptide [PACAP] analogue) that has a high affinity for VPAC1 receptors expressed on cancer cells.
Chen, Chang-Po +6 more
core +2 more sources
The next generation of peptide receptor radionuclide therapy [PDF]
Endocrine-Related Cancer, 2019 Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-[Tyr3]octreotate has been successfully developed in the last decades for the treatment of neuroendocrine neoplasms. However, different methods to improve the objective response rate and survival are under investigation.
Brabander, Tessa +2 more
openaire +3 more sources
EJNMMI Research, 2018 Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation.
Daphne Merel Valerie Huizing +3 more
doaj +1 more source
Iodine-131 labelled octreotide: Not an option for somatostatin receptor therapy [PDF]
, 1996 Gamma-emitting radiopeptides are useful for scintigraphy of tumours on the basis of receptor binding. Likewise, β-emitting radiopeptides may be used in radionuclide therapy of such tumours.
Bakker, W.H. (Willem) +5 more
core +1 more source
Treatment options for PNET liver metastases. a systematic review [PDF]
, 2018 Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo +8 more
core +1 more source
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
EJNMMI Research, 2022 Background Somatostatin receptor 68Ga PET imaging is standard for evaluation of a patient’s suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine tumours (NETs).
Anna Stenvall +8 more
doaj +1 more source
Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2020 We present the case of a 60-year-old man with metastatic neuroendocrine tumor of the ileum following ileal resection, being evaluated for 177Lu-based peptide receptor radionuclide therapy.
Ashwin Parihar +4 more
doaj +1 more source
Preclinical animal research on therapy dosimetry with dual isotopes [PDF]
, 2011 Preclinical research into radionuclide therapies based on radiation dosimetry will enable the use of any LET-equivalent radionuclide. Radiation dose and dose rate have significant influence on dose effects in the tumour depending on its radiation ...
Mark W. Konijnenberg, Marion de Jong
core +4 more sources
Practical Guidance on Peptide Receptor Radionuclide Therapy
Nuclear Medicine Seminars, 2020 Peptide receptor radionuclide therapy (PRRT) have been successfully used for the past 20 years to target metastatic or inoperable neuroendocrine tumors expressing the somatostatin receptors. Both prospective and retrospective studies indicate that patients receiving PRRT show significantly high objective responses, leading to longer survival and ...
Emre Demirci +6 more
openaire +1 more source